Table 1 Patient characteristics
Overall (N = 10) | Stable disease (N = 4) | Progressive disease (N = 6) | |
|---|---|---|---|
Age years median [range] | 63 [19–75] | 69 [19–75] | 60 [42–73] |
Male N (%) | 4/10 (40%) | 1/4 (25%) | 3/6 (50%) |
RET | |||
Wild-type N (%) | 6/10 (60%) | 3/4 (75%) | 3/6 (50%) |
Unknown N (%) | 4/10 (40%) | 1/4 (25%) | 3/6 (50%) |
Disease extent | |||
Moderate | 8/10 (80%) | 2/4 (50%) | 6/6 (100%) |
Extensive | 2/10 (20%) | 2/4 (50%) | 0/6 (0%) |
Tumormarkers | |||
Calcitonin DT years, [range] | 2.4 [0.6–4.1] | 0.8 [0.6–4.1] | 2.6 [2.4–2.9] |
CEA DT years, [range] | 1.9 [0.6–7.4] | 1.9 [1.2–2.1] | 4.0 [0.6–7.4] |
PRRT indication | |||
PD | 8/10 (70%) | 3/4 (75%) | 5/6 (83%) |
Tumor localization❶ | 2/10 (30%) | 1/4 (25%) | 1/6 (17%) |
WHO | |||
1 | 8/10 (80%) | 3/4 (75%) | 5/6 (83%) |
3 | 2/10 (20%) | 1/4 (25%) | 1/6 (17%) |
Hormonal functioning ❷ | 3/10 (30%) | 1/4 (25%) | 2/6 (33%) |
Endpoints | |||
Death from MTC | 7/10 | 2/4 (50%) | 5/6 (83%) |
Death other cause❸ | 1/10 | 1/4 (25%) | 0/4 (0%) |
Alive | 2/10 | 1/4 (25%) | 1/4 (25%) |